Immunoglobulin a IgA Vasculitis Market Report 2026

The immunoglobulin a iga vasculitis market size has grown strongly in recent years. It will grow from $1.63 billion in 2025 to $1.74 billion in 2026 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to improved clinical understanding of iga-mediated autoimmune disorders, increased diagnosis of pediatric vasculitis cases, wider use of corticosteroids and immunosuppressants, growth of hospital-based autoimmune care, expanding nephrology clinical expertise.

The immunoglobulin a iga vasculitis market size is expected to see strong growth in the next few years. It will grow to $2.21 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to rising research on novel immunomodulatory drugs, increasing adoption of personalized autoimmune therapies, growing focus on long-term renal protection, expansion of biologic treatment pipelines, improved diagnostic imaging and biopsy techniques. Major trends in the forecast period include increasing focus on early and accurate disease diagnosis, rising adoption of targeted immunosuppressive therapies, growing use of biomarker-based disease monitoring, expansion of personalized treatment approaches, enhanced emphasis on renal outcome management.

The increasing incidence of autoimmune diseases is expected to drive the growth of the immunoglobulin A (IgA) vasculitis market in the coming years. Autoimmune diseases are disorders in which the immune system incorrectly targets the body’s own healthy cells, tissues, or organs rather than defending against infections and foreign agents. The growing prevalence of autoimmune conditions is largely attributed to increased exposure to environmental pollutants, which can interfere with immune regulation and provoke abnormal immune responses. Immunoglobulin A (IgA) vasculitis contributes to autoimmune disease research and management by initiating immune responses that cause inflammation in small blood vessels, supporting the understanding and potential treatment of various autoimmune disorders. For example, in February 2024, according to the Vasculitis Foundation, a US-based non-profit organization, the annual incidence of IgA vasculitis among adults in the U.S. is approximately 2 cases per 100,000 people, although global rates vary significantly, ranging from about 60 to 550 cases per million. Therefore, the rising incidence of autoimmune diseases is fueling the growth of the immunoglobulin A (IgA) vasculitis market.

The growing emphasis on targeted therapies is expected to propel the growth of the immunoglobulin A (IgA) vasculitis market. Targeted therapies are treatments designed to specifically inhibit molecular abnormalities associated with cancer or other diseases, improving therapeutic precision while reducing damage to healthy cells. The increasing focus on targeted therapies is mainly driven by advancements in precision medicine, which enable personalized and more effective treatments based on individual genetic characteristics. Targeted therapies support the treatment of immunoglobulin A (IgA) vasculitis by acting on specific immune pathways, thereby limiting systemic side effects. They enhance disease management by reducing inflammation and preventing organ damage, ultimately improving patient outcomes and quality of life. For instance, in December 2024, according to the American Society of Gene and Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, the Food and Drug Administration (FDA) approved six gene therapy products in 2023, compared with five approvals in 2022. Therefore, the increasing focus on targeted therapies is driving the growth of the immunoglobulin A (IgA) vasculitis market.

Major companies operating in the immunoglobulin A (IgA) vasculitis market are concentrating on the development of innovative treatments, such as targeted biologics and immunomodulators, to reduce inflammation and prevent kidney-related complications. Targeted biologics and immunomodulators are advanced therapies that regulate specific immune pathways to control inflammation and prevent immune-mediated damage in IgA vasculitis. For example, in April 2025, Novartis AG, a Switzerland-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Vanrafia (atrasentan) for the treatment of primary immunoglobulin A nephropathy (IgAN). Vanrafia is a once-daily, oral, selective endothelin A receptor antagonist developed to reduce proteinuria in adults with primary IgAN who are at risk of rapid disease progression. It can be incorporated into existing supportive care regimens without requiring a risk evaluation and mitigation strategy (REMS).

Major companies operating in the immunoglobulin a iga vasculitis market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc, Intas Pharmaceuticals Ltd, Zydus Lifesciences Limited, Biogen Inc, Chugai Pharmaceutical Co Ltd, CSL Behring, AbbVie Inc, Johnson & Johnson, Bristol-Myers Squibb Company, UCB SA, Sanofi, GSK plc, Astellas Pharma Inc, Teva Pharmaceuticals USA Inc, Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co Ltd, Visterra Inc, Selecta Biosciences, Jiangsu HengRui Medicine Co Ltd, Travere Therapeutics Inc, Everest Medicines Ltd.

North America was the largest region in the immunoglobulin A (IgA) vasculitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulin a iga vasculitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the immunoglobulin a iga vasculitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the immunoglobulin a iga vasculitis market by increasing costs of imported biologics, immunosuppressive drugs, diagnostic reagents, and laboratory equipment used in disease diagnosis and management. Hospitals and specialty clinics in North America and Europe are most affected due to dependence on imported pharmaceuticals and diagnostic tools, while Asia-Pacific faces higher costs for advanced biologics. These tariffs are raising treatment expenses and affecting reimbursement dynamics. However, they are also encouraging domestic drug manufacturing, regional clinical research investments, and localized production of diagnostic consumables, supporting long-term supply chain resilience.

The immunoglobulin a iga vasculitis market research report is one of a series of new reports that provides immunoglobulin a iga vasculitis market statistics, including immunoglobulin a iga vasculitis industry global market size, regional shares, competitors with a immunoglobulin a iga vasculitis market share, detailed immunoglobulin a iga vasculitis market segments, market trends and opportunities, and any further data you may need to thrive in the immunoglobulin a iga vasculitis industry. This immunoglobulin a iga vasculitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Immunoglobulin A (IgA) vasculitis is an autoimmune disorder characterized by inflammation of small blood vessels, primarily caused by the deposition of IgA antibodies. It commonly affects the skin, joints, kidneys, and gastrointestinal tract and is marked by symptoms such as a purplish rash, abdominal pain, and joint inflammation.

The primary treatment types of immunoglobulin A (IgA) vasculitis include medications, plasma exchange, supportive care, and immunosuppressive therapy. Medications are mainly used to reduce inflammation and relieve symptoms such as joint pain, skin rashes, and kidney-related complications arising from IgA deposits in small blood vessels that activate immune responses. Diagnostic approaches typically include blood tests, urinalysis, imaging studies, and tissue biopsy. Treatment is administered through oral, injectable, and intravenous routes and is provided across various healthcare settings, including hospitals, specialty clinics, and homecare environments.

The immunoglobulin A (IgA) vasculitis market consists of revenues earned by entities by providing services such as diagnostic testing, renal function monitoring, patient management programs, and clinical research and trials for novel therapeutics. The market value includes the value of related goods sold by the service provider or included within the service offering. The immunoglobulin A (IgA) vasculitis market also includes sales of corticosteroids, pain relievers, diagnostic kits, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.